Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Dr. Charles Turck and Dr. Petros Grivas discuss the role of urinary and circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer, referencing data from the NIAGARA trial. They explore how perioperative durvalumab affects ctDNA clearance and clinical outcomes, and the…